The New York company, which counts 45 Fortune 500 companies as clients, pitches a pharmacy benefit model that caps total pharmacy spend and prices GLP-1s and rare high-cost drugs at net cost.
The joint venture moved from plans to serving customers on MI355X systems, with MI400-series capacity due from the second half of 2027 and a 1 gigawatt target by 2030.
